December 12, 2013
An FDA panel meets Tuesday to consider pulling the diabetes drug Avandia from the market.
Dozens of studies have linked the former GlaxoSmithKline best-seller to an increased risk of heart attack.
Government scientists say studies conducted by the company are flawed and actually make the case against Avandia.
The panel will make its recommendation to the FDA after a two-day review of the drug's performance.
|Get the ingredients you need to cook with Rach all week long.|
|Full length exclusive concerts from hot artists.|
|Take a break!
Classic Pacman, Frogger, Asteroids and more.
Sell almost anything locally.